Mallinckrodt (MNK) PT Lowered to $87 at Mizuho Ahead of Q3 Print
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
FDA denies Mallinckrodt (MNK) citizens petition regarding INOMAX
November 23, 2016 3:19 PM ESTFDA denies Mallinckrodt (NYSE: MNK) citizens petition regarding INOMAX.
... More
Mallinckrodt (MNK) to Initiate Company-Sponsored Clinical Trial of Acthar in ALS; FDA Grants Fast Track Status
November 21, 2016 7:02 AM ESTMallinckrodt plc (NYSE: MNK) confirmed that it will initiate a company-sponsored, Phase 2 proof-of-concept clinical trial to assess the efficacy of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotropic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease). The study is expected to begin in the first half of 2017.
Mallinckrodt also announced the U.S. Food and Drug Administration (FDA) has... More
